Targeted drug treatment after gallbladder surgery using blood test monitoring
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests a targeted treatment (GEMOX) given after gallbladder cancer surgery. It uses a blood test that looks for cancer-related DNA to monitor recurrence and guide care, aiming to improve outcomes for people with higher-risk disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had gallbladder cancer surgery, and the diagnosis was confirmed under a microscope.
- Your scans and exam suggest higher-risk disease (stage T2 or lymph nodes positive).
- Your tumor’s genetic testing shows certain abnormal changes in the ERBB2 (ERb-B2) growth-signaling pathway.
- You can provide fresh tumor tissue for genetic testing and an immune marker test.
- You are generally well enough to join (ECOG 0–1) and can live safely for at least 18 weeks.
- Your liver, blood counts, and kidneys meet lab safety thresholds.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
This Phase 2 trial tests a combination of three medicines (GEMOX, donafenib, and tislelizumab) for advanced bile duct cancer. It aims to see if the treatment can shrink tumors and improve outcomes in people with certain tumor stage and health test results.
This trial tests different treatments for advanced bile duct or gallbladder cancer based on individual tumor features. It may help people who have not had prior therapy for their cancer.
This trial tests a combination of two chemotherapy drugs (gemcitabine and nab-paclitaxel) with two immunotherapy drugs (iparomlimab and tuvorilimab) for people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink the cancer or slow its growth.
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
This trial tests whether giving a drug that blocks blood vessel growth (anti-angiogenic therapy) after immunotherapy can help people with advanced bile duct, gallbladder, or cholangiocarcinoma that cannot be removed by surgery. The goal is to see if this sequence improves outcomes for patients who have not had prior treatment for advanced disease.
Hear when a new Gallbladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.